Zelira Therapeutics (ASX:ZLD) received a $1.4 million working capital loan from Chairman Osagie Imasogie, according to a Thursday filing with the Australian bourse.
The unsecured debt will become a convertible loan bond at $0.40 per share, subject to shareholder approval. This represents a more than 100% premium to the closing price on June 28, based on a July 1 filing.
Funds are for the advancement of the HOPE special purpose vehicle clinical trial.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments